GNMX - Aevi Genomic Medicine, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.1925
+0.0007 (+0.36%)
As of 1:35PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.1918
Open0.1910
Bid0.1864 x 3000
Ask0.1874 x 800
Day's Range0.1802 - 0.1980
52 Week Range0.1700 - 1.7200
Volume435,239
Avg. Volume1,889,200
Market Cap12.468M
Beta (3Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)-0.4290
Earnings DateMay 8, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.58
Trade prices are not sourced from all markets
  • ACCESSWIRE2 months ago

    These Four Healthcare Stocks are Surging with Potential

    CORAL GABLES, FL / ACCESSWIRE / March 12, 2019 / The healthcare stock market is comprised of innovative companies working diligently to design, manufacture, and commercialize state-of-the-art tech-driven solutions for the healthcare industry. It is the responsibility of healthcare companies to meet the oncoming challenges presented by infectious diseases and ailments, and so long as they can meet these requirements, the healthcare sector could generate market excitement. Premier Health Group (OTC:PHGRF) (CSE:PHGI), ENDRA Life Sciences Inc (NDRA), Novavax Inc (NVAX), and Aevi Genomic Medicine Inc (GNMX) are 4 healthcare companies raising the bar on Tuesday.

  • GlobeNewswire3 months ago

    Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Zacks Small Cap Research4 months ago

    GNMX: ASCEND Misses Primary Endpoint: GNMX indicates they are not giving up in AEVI-001

    On January 2nd Aevi (GNMX) announced that ASCEND, the phase II trial evaluating their non-stimulant glutamatergic neuromodulator in pediatric and adolescent subjects with ADHD, failed to meet its primary endpoint of a statistically significant reduction of ADHD-RS at 6 weeks in either Part A (mGluR+ subjects) or Part B (mutation free subjects). As we have consistently stated in our coverage, given the largely positive results of SAGA and enrichment of ASCEND with only patients with mutations to nine select genes in the mGluR network, along with a pediatric weighting, we had expected ASCEND would prove successful. As a reminder about SAGA’s results (see link to our report), it did meet statistical significance on the CGI-I secondary endpoint as well as on the ADHD-RS responder measure (prespecified as decrease of ADHD-RS score of 30% or more, which is considered a clinical response).

  • ACCESSWIRE4 months ago

    The Next Big Biotech Breakout

    HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Celgene's major deal with Bristol-Myers Squibb seems to have woken up the sleeping giant that is the biotech market. Axsome announced positive trial data ...

  • Benzinga5 months ago

    The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen

    Bristol-Myers Squibb Co (NYSE: BMY) announced a deal to buy Celgene Corporation (NASDAQ: CELG) in a cash and stock transaction with an equity value of approximately $74 billion. Separately, the company announced FDA approval for an expanded indication for its Sprycel tablets to include the treatment of pediatric patients one year of age and older, with newly diagnosed Philadelphia chromosome-positive, or Ph+, acute lymphoblastic leukemia in combination with chemotherapy.

  • PR Newswire5 months ago

    Aevi Genomic Medicine Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD

    PHILADELPHIA, Jan. 2, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) ("the Company") today announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 – 400 mg BID) in children aged 6 – 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant (Part A) or without an mGluR copy number variant (Part B), did not achieve statistical significance on the primary endpoint of reduction of ADHD-RS in either Part A or Part B after 6 weeks of treatment with AEVI-001.  AEVI-001 was safe and well tolerated. Reported adverse events were minimal and similar across both Part A and Part B treatment groups.

  • ACCESSWIRE5 months ago

    4 Pharma Stocks Getting a Boost on Thursday (12/20/18)

    CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The healthcare industry is complicated, this much is certain, but amidst the complexities exist innovative approaches to healthcare that will ultimately provide the best quality of care for patients in the future. From advancements in the nascent telehealth industry to improved treatment options for patients, the healthcare sector may offer significant opportunities in the near future. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aevi Genomic Medicine, Inc (GNMX), Aurinia Pharmaceuticals, Inc (AUPH), and CV Sciences, Inc (CVSI) are 4 pharma stocks to pay attention to heading into the rest of the week.

  • PR Newswire6 months ago

    Aevi Genomic Medicine to Host KOL Breakfast to Discuss Diagnosis and Treatment Paradigms in ADHD

    PHILADELPHIA, Nov. 26, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) (the Company) announced today that the Aevi Genomic Medicine Management team will host a breakfast with Key Opinion Leader (KOL) Robert Findling, M.D., Leonard and Helen R. Stulman Professor in Child and Adolescent Psychiatry at Johns Hopkins University.  During the breakfast they will discuss the diagnosis and treatment paradigms in Attention Deficit Hyperactivity Disorder (ADHD).  The breakfast is being held on Thursday, November 29, 2019 at 8:00 AM EST at the National in New York, New York. Aevi Genomic Medicine, Inc. is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the Company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP).

  • GlobeNewswire6 months ago

    Detailed Research: Economic Perspectives on Gogo, Aevi Genomic Medicine, PBF Energy, SiteOne Landscape Supply, Douglas Dynamics, and Dine Brands Global — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Zacks Small Cap Research6 months ago

    GNMX: With ASCEND Enrollment Completed, Read-Out Expected In Q1’19

    Aevi Genomic Medicine (GNMX) reported Q3 financial results and provided a business update. Just two months later, GNMX announced that part ‘B’ (i.e. Also noteworthy is that while the initial plan was for parts A and B to enroll and read-out sequentially, given the rapid enrollment of part B, the expectation is now that top-line data will be announced for both in January.

  • Associated Press7 months ago

    Aevi Genomic Medicine: 3Q Earnings Snapshot

    On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 12 cents. The company's shares closed at $1.09. A year ago, they were trading at $1.66. _____ This story was generated ...

  • PR Newswire7 months ago

    Aevi Genomic Medicine Reports Third Quarter 2018 Financial Results and Provides Business Update

    PHILADELPHIA , Nov. 1, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended September ...

  • PR Newswire7 months ago

    Aevi Genomic Medicine Announces Completion of Enrollment for Part B of the ASCEND Trial

    PHILADELPHIA, Oct. 15, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) (the Company) today announced that it has reached full enrollment of Part B of its Phase 2 ASCEND clinical trial.  The ASCEND trial is a genomically-guided study in pediatric and adolescent patients with Attention Deficit Hyperactivity Disorder (ADHD) assessing the safety and efficacy of AEVI-001, a novel, non-stimulant therapy. Part B of the ASCEND trial is studying pediatric and adolescent patients with ADHD without mGluR mutations.

  • PR Newswire9 months ago

    Aevi Genomic Medicine to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    PHILADELPHIA , Aug. 29, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the H.C. ...

  • PR Newswire9 months ago

    Aevi Genomic Medicine Announces Capital Raise of $4.9M to Accelerate Part B of the ASCEND Trial

    PHILADELPHIA, Aug. 21, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (GNMX) (the Company) today announced the sale of 5.1 million shares of its common stock for aggregate proceeds of $4.9 million, before expenses. The sales were through the Company's existing ATM program, for which JMP Securities LLC acts as the Company's sales agent. The Company recently announced the completion of enrollment in Part A of the ASCEND trial and intends to use the net proceeds raised from the ATM to accelerate Part B of the ASCEND trial.

  • PR Newswire9 months ago

    Aevi Genomic Medicine Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD

    "We are pleased that we have completed enrollment in Part A of our ASCEND trial" said Garry A. Neil, M.D., Chief Scientific Officer of Aevi Genomic Medicine. ASCEND is an adaptive, 6-week, double-blind parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without copy number variants (CNVs) in specific genes implicated in glutamatergic signaling and neuronal connectivity.

  • Zacks Small Cap Research9 months ago

    GNMX: AEVI Q2 Update: ASCEND Data By Year-End, Enhanced 001 Co-Crystal

    Despite the slight additional delay to ASCEND (as a result of the optioned increased enrollment), we continue to think there may be several pipeline-related events over the very near term that could potentially favorably influence equity valuation and related pricing of any near-term financings. GNMX hopes to swap out AEVI-001 (which is in phase 2 mGlur+ ADHD ASCEND study) with an improved version. AEVI-004 provides the benefits of intellectual property protection (out to 2039) and is designed to maintain substantially similar solubility, dissolution and pharmakokinetics of AEVI-001 but with (per GNMX's press release) "greater stability and a higher melting point".

  • Associated Press10 months ago

    Aevi Genomic Medicine: 2Q Earnings Snapshot

    On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 14 cents. The company's shares closed at $1.10. A year ago, they were trading at $1.20. _____ This story was generated ...

  • PR Newswire10 months ago

    Aevi Genomic Medicine Reports Second Quarter 2018 Financial Results and Provides Business Update

    PHILADELPHIA , Aug. 2, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended June 30 , ...

  • PR Newswire10 months ago

    Aevi Genomic Medicine, Inc. Announces Novel Co-crystal Version of AEVI-001

    -FDA provisionally agreed that AEVI-004 is a co-crystal and a novel drug substance -FDA provisionally agreed existing AEVI-001 toxicology and pathology studies are acceptable to support clinical development ...

  • Zacks Small Cap Research11 months ago

    GNMX: ASCEND Will Enroll To N=64, (consistent with initial trial design)

    Indicating that after an interim look at the placebo arm, the decision was made to continue to enroll to n=64 in order to “ensure sufficient power to detect a robust treatment effect”. In other words, in order to further reduce the risk of placebo effect. Importantly, this decision was based solely on a statistically-derived estimate of placebo response based solely on the placebo arm (i.e.

  • PR Newswire11 months ago

    Aevi Genomic Medicine to Present at the The 2018 JMP Securities Life Sciences Conference

    PHILADELPHIA , June 13, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the ...

  • Aevi Genomic Medicine Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD
    PR Newswire11 months ago

    Aevi Genomic Medicine Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD

    The decision to increase the sample size was made according to the protocol defined sample size re-estimatation design, which allows an adjustment in the sample size after an interim analysis of the placebo arm to ensure the trial is appropriately powered.  As a result of the interim analysis performed by an independent unblinded statistician, the sample size will be increased from 42 to 64 patients.

  • Zacks Small Cap Research11 months ago

    GNMX: Development Timelines Intact, Including AEVI-001 Ph2 ADHD Data Expected ~Mid-Year

    By Brian Marckx, CFA NASDAQ:GNMX READ THE FULL RESEARCH REPORT Q1 2018 Results / Operational Update : Pipeline Development Timelines Tracking Prior Expectations… Aevi Genomic Medicine (NASDAQ:GNMX) reported ...